Serine ADP-ribosylation in DNA-damage response regulation.
Journal
Current opinion in genetics & development
ISSN: 1879-0380
Titre abrégé: Curr Opin Genet Dev
Pays: England
ID NLM: 9111375
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
21
05
2021
revised:
01
07
2021
accepted:
05
07
2021
pubmed:
3
8
2021
medline:
5
4
2022
entrez:
2
8
2021
Statut:
ppublish
Résumé
PARP1 and PARP2 govern the DNA-damage response by catalysing the reversible post-translational modification ADP-ribosylation. During the repair of DNA lesions, PARP1 and PARP2 combine with an accessory factor HPF1, which is required for the modification of target proteins on serine residues. Although the physiological role of individual ADP-ribosylation sites is still unclear, serine ADP-ribosylation at damage sites leads to the recruitment of chromatin remodellers and repair factors to ensure efficient DNA repair. ADP-ribosylation signalling is tightly controlled by the coordinated activities of (ADP-ribosyl)glycohydrolases PARG and ARH3 that, by reversing the modification, guarantee proper kinetics of DNA repair and cell cycle re-entry. The recent advances in the structural and mechanistic understanding of ADP-ribosylation provide new insights into human physiopathology and cancer therapy.
Identifiants
pubmed: 34340015
pii: S0959-437X(21)00091-5
doi: 10.1016/j.gde.2021.07.005
pii:
doi:
Substances chimiques
Carrier Proteins
0
HPF1 protein, human
0
Nuclear Proteins
0
Serine
452VLY9402
DNA
9007-49-2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
106-113Subventions
Organisme : Wellcome Trust
ID : 210634
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 101794
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/R007195/1
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C35050/A22284
Pays : United Kingdom
Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.